Merck Acquires Terns Pharmaceuticals for $6.7 Billion to Expand Cancer Drug Portfolio
25.03.2026, 14:00
Merck has finalized a $6.7 billion acquisition of Terns Pharmaceuticals, significantly enhancing its cancer drug pipeline, particularly in the area of hematology with the addition of TERN-701, a novel candidate for chronic myeloid leukemia (CML). This strategic move comes as Merck seeks to diversify...